AU2001275679A1 - Methods and compounds for influencing beta3 integrin-dependent intracellular processes - Google Patents

Methods and compounds for influencing beta3 integrin-dependent intracellular processes

Info

Publication number
AU2001275679A1
AU2001275679A1 AU2001275679A AU7567901A AU2001275679A1 AU 2001275679 A1 AU2001275679 A1 AU 2001275679A1 AU 2001275679 A AU2001275679 A AU 2001275679A AU 7567901 A AU7567901 A AU 7567901A AU 2001275679 A1 AU2001275679 A1 AU 2001275679A1
Authority
AU
Australia
Prior art keywords
influencing
compounds
methods
beta3
intracellular processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275679A
Inventor
Meinrad Gawaz
Waldemar Kolanus
Martin Ungerer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procorde GmbH
Original Assignee
Procorde GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10037272A external-priority patent/DE10037272A1/en
Application filed by Procorde GmbH filed Critical Procorde GmbH
Publication of AU2001275679A1 publication Critical patent/AU2001275679A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the use of beta3-endonexin-long or beta3-endonexin-short for finding active substances for the treatment of arteriosclerosis, unstable plaques resulting from the latter, acute coronary thrombosis, cardiac infarct, stroke, peripheral arterial occlusion diseases, chronic venous ulcer and restenosing processes.
AU2001275679A 2000-06-09 2001-06-11 Methods and compounds for influencing beta3 integrin-dependent intracellular processes Abandoned AU2001275679A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10028645 2000-06-09
DE10028645 2000-06-09
DE10037272A DE10037272A1 (en) 2000-06-09 2000-07-28 Identifying agents for treating cardiovascular disease, comprises determining the ability of potential agents to modify interaction between beta3 endonexin and beta3 integrin
DE10037272 2000-07-28
PCT/EP2001/006588 WO2001094613A2 (en) 2000-06-09 2001-06-11 Methods and compounds for influencing beta3 integrin-dependent intracellular processes

Publications (1)

Publication Number Publication Date
AU2001275679A1 true AU2001275679A1 (en) 2001-12-17

Family

ID=26006039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275679A Abandoned AU2001275679A1 (en) 2000-06-09 2001-06-11 Methods and compounds for influencing beta3 integrin-dependent intracellular processes

Country Status (6)

Country Link
US (1) US20040029775A1 (en)
EP (1) EP1287355B1 (en)
JP (1) JP2004511755A (en)
AT (1) ATE265044T1 (en)
AU (1) AU2001275679A1 (en)
WO (1) WO2001094613A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318017A1 (en) * 2008-08-20 2011-05-11 New York Blood Center, Inc. Regulation of integrin surface expression

Also Published As

Publication number Publication date
ATE265044T1 (en) 2004-05-15
WO2001094613A3 (en) 2002-06-20
US20040029775A1 (en) 2004-02-12
EP1287355B1 (en) 2004-04-21
WO2001094613A2 (en) 2001-12-13
EP1287355A2 (en) 2003-03-05
JP2004511755A (en) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0108452A (en) Fatty acid partial oxidation inhibitors in the treatment of congestive heart failure
ATE411831T1 (en) MULTIPLE SIGNAL PATTERNS FOR FILTERING FAR FIELD R-WAVES
EP0771565A3 (en) Angiogenesis inhibitor
DE60019473D1 (en) (S, S) reboxetine for the treatment of peripheral neuropathies
ATE462424T1 (en) THERAPEUTIC USE OF NEBULATED S-NITROSOGLUTATHIONE IN CYSTIC FIBROSIS
DE60101265D1 (en) TREATMENT OF EYE PAIN
DE60139466D1 (en) TREATMENT OF DIABETES
CY1109191T1 (en) A NEW USE OF DIFFERIPRON
ITTO950104A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
WO2003103662A3 (en) Inhibitors of glycoprotein vi
ITTO950099A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
AU2001275679A1 (en) Methods and compounds for influencing beta3 integrin-dependent intracellular processes
DE60045638D1 (en) AVOIDANCE AND TREATMENT OF DISEASES RELATED TO THE BLOODS
MXPA03003980A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders.
HUP0003831A2 (en) Tissue factor for influencing blood vessel formation
DE60201440D1 (en) ARYL-8-AZABICYCLO [3.2.1] OCTANES FOR THE TREATMENT OF DEPRESSION
DE60017174D1 (en) RIVASTIGMINE FOR THE TREATMENT OF EYE DISEASES
WO2001056593A3 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
WO2000043028A3 (en) Method of treating chronic cardiac disease
ATE343387T1 (en) S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF EYE DISEASES.
ATE319455T1 (en) VITAMIN D COMPOUNDS FOR THE TREATMENT OF CHRONIC TRANSPLANT TENEPHROPATHY IN KIDNEY TRANSPLANT PATIENTS
WO1997004790A3 (en) Drug for use in the treatment of ulcers containing magnesium ions as active substance
FR2860234B1 (en) NEW THIOXYLOSE DERIVATIVES 666
TR200103526T2 (en) Aminotetralin derivative for the therapy of cardiovascular diseases.
AP1708A (en) Method for preventing or delaying catheter-based revascularization.